42,281 results match your criteria Non-Hodgkin Lymphoma Thoracic


Microfluidic assembly of hydrogel-based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release.

J Control Release 2018 Dec 11. Epub 2018 Dec 11.

Department of Pharmaceutical Sciences, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA. Electronic address:

Diffuse large B cell lymphoma (DLBCL), the most common subtype of Non-Hodgkin lymphoma, exhibits pathologic heterogeneity and a dynamic immunogenic tumor microenvironment (TME). However, the lack of preclinical in vitro models of DLBCL TME hinders optimal therapeutic screening. This study describes the development of an integrated droplet microfluidics-based platform for high-throughput generation of immunogenic DLBCL spheroids. Read More

View Article
December 2018
1 Read

Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: a series of 4 cases.

Dermatol Ther 2018 Dec 14:e12804. Epub 2018 Dec 14.

Cutaneous Lymphoma Program, Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA.

Cutaneous T-cell lymphomas (CTCL) are a relatively rare and heterogeneous group of non-Hodgkin lymphomas that typically present in the skin. The majority of patients with CTCL experience pruritus, which can interfere with daily activities, significantly impact quality of life, and is typically uncontrolled by standard anti-itch therapies. Several lymphoma treatments have reported anti-pruritic effects including romidepsin, a potent class 1 selective histone deacetylase inhibitor approved for the treatment of patients with CTCL who have had at least 1 prior systemic therapy. Read More

View Article
December 2018
1 Read

Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.

Br J Haematol 2018 Dec 13. Epub 2018 Dec 13.

Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.

Delayed lymphocyte and T-cell immune reconstitution following bendamustine-rituximab (BR) for indolent non-Hodgkin lymphoma (iNHL) has been described, but no information is available for chronic lymphocytic leukaemia (CLL). We present a population-based retrospective analysis of immune reconstitution and risk of infection following BR. Outcomes included timing/correlates of CD4+ recovery and risk of ≥grade 3 infections. Read More

View Article
December 2018

Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.

Cancer 2018 Dec 12. Epub 2018 Dec 12.

Department of Public Health Sciences, The University of Chicago, Chicago, Illinois.

Background: Granulocyte colony-stimulating factors (G-CSFs), which are used for the prevention of complications from chemotherapy-related neutropenia, are linked to the risk of developing second primary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The objective of this study was to examine the correlation between using a specific G-CSF agent and the risk of MDS/AML among older patients with non-Hodgkin lymphoma (NHL).

Methods: This was a retrospective cohort study of adults aged >65 years who were diagnosed with first primary NHL between 2001 and 2011. Read More

View Article
December 2018

Cause-specific mortality among medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes.

Cancer 2018 Dec 11. Epub 2018 Dec 11.

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Background: As the US population ages and non-Hodgkin lymphoma (NHL)-specific mortality declines, deaths from causes other than NHL will become increasingly important in treatment decision making for older patients with NHL. The objective of the current study was to describe how the 5-year cumulative incidence of NHL-specific and other-cause mortality varies by subtype, age, comorbidity level, and time since diagnosis in older patients.

Methods: Using the Surveillance, Epidemiology, and End Results cancer registry data linked to Medicare claims, patients aged ≥66 years were identified at the time of diagnosis with a first, primary NHL diagnosis from 2004 through 2013. Read More

View Article
December 2018

A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma.

Leuk Lymphoma 2018 Dec 14:1-8. Epub 2018 Dec 14.

j Department of Haematology , Peter MacCallum Cancer Centre , Melbourne , Australia.

To improve complete remission (CR) rates by reducing toxicity and enhancing delivery, we created a modified hyper-CVAD/MA regimen (cyclophosphamide, vincristine, doxorubicin, dexamethasone/methotrexate, cytarabine) by reducing the cytarabine dose (3 g/m to 2 g/m) and number of cycles (eight to six). We conducted a phase II trial in the pre-rituximab era in the intermediate-high international prognostic index (IPI) (≥2) de novo diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL) (ACTRN12605000105640). CR rates were compared with reported IPI-stratified rates. Read More

View Article
December 2018
1 Read

Gadolinium-enhanced imaging of pediatric thoracic lymphoma: is intravenous contrast really necessary?

Eur Radiol 2018 Dec 13. Epub 2018 Dec 13.

Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt/Main, Germany.

Objectives: Increasing awareness of potential side effects from gadolinium-based contrast agents has underlined the need for contrast-free magnetic resonance imaging (MRI). Numerous recent articles evaluated the risk of potential brain deposits, with the result that research is putting the focus more on alternative unenhanced imaging techniques. The aim of this study was to determine the need for contrast media for chest MRI in primary staging and follow-up care of lymphoma. Read More

View Article
December 2018
1 Read

Levels of regulatory T cells and invariant natural killer cells and their associations with regulatory B cells in patients with non-Hodgkin lymphoma.

Mol Clin Oncol 2018 Dec 2;9(6):677-682. Epub 2018 Oct 2.

Department of Haematology, Sultan Qaboos University Hospital, College of Medicine and Health Sciences, Muscat 123, Sultanate of Oman.

Due to their immunoregulatory properties, several specialized cell subsets, including regulatory T (Treg), invariant natural killer T (iNKT) and regulatory B (Breg) cells, are involved in the pathogenesis of non-Hodgkin lymphoma (NHL). However, the interaction between various cells remains to be elucidated. The aim of the present study was to evaluate the levels of Treg, iNKT and Breg cell subsets and their interrelationships in the peripheral blood (PB) and bone marrow (BM) of patients with B-cell NHL who received rituximab-based regimens and achieved a complete remission. Read More

View Article
December 2018

Primary extra-nodal non-Hodgkin lymphoma in buttock soft tissue: A rare case report.

Medicine (Baltimore) 2018 Dec;97(49):e13550

Head of the Central Laboratory of Hebei University, Hebei province, China.

Rationale: Primary extra-nodal non-Hodgkin lymphoma (PE-NHL) arising in the region of the buttocks is rare. After reviewing the literature from the last 20 years, we found only 3 reported lymphomas originating from soft tissue of the buttocks. In our case, positron emission tomography/computed tomography (PET/CT) was performed for the first time, both before and after treatment, to determine the initial stage of PE-NHL and the curative effects of treatment. Read More

View Article
December 2018

Primary cutaneous anaplastic large cell lymphoma arising from a long-standing erythema nodosum: A case report.

Medicine (Baltimore) 2018 Dec;97(49):e13211

Department of Hematology.

Rationale: Primary cutaneous anaplastic large cell lymphoma (pcALCL) is a rare subtype of non-Hodgkin lymphoma, which is rarely associated with erythema nodosum (EN).

Patient Concerns: A 57-year-old woman complained of recurrent rashes involving her abdomen, back, upper and lower limbs for over 20 years, with severity in symptoms for 2 weeks.

Diagnoses: The first skin biopsy was performed in 2011 in another hospital and she was diagnosed idiopathic EN. Read More

View Article
December 2018

Loncastuximab tesirine in patients with B-cell non-Hodgkin lymphoma.

Authors:
Brad S Kahl

Clin Adv Hematol Oncol 2018 Nov;16(11):732-734

Lymphoma Program, Washington University School of Medicine, St Louis, Missouri.

View Article
November 2018

Plasmablastic Lymphoma in an Immunocompetent Patient with MDS/MPN with Ring Sideroblasts and Thrombocytosis-A Case Report.

Case Rep Hematol 2018 4;2018:2525070. Epub 2018 Nov 4.

Second Department of Internal Medicine and Research Unit, University General Hospital "Attikon", 1 Rimini St., Haidari, 12462 Athens, Greece.

Plasmablastic lymphoma (PBL) is a rare, aggressive type of B-cell non-Hodgkin lymphoma with the vast majority of patients responding poorly to treatment or progressing shortly thereafter. Cyclophosphamide-doxorubicin-vincristine-prednisolone (CHOP) or CHOP-like regimens have disappointing results in this setting. We report a case of PBL arising in a previously diagnosed myelodysplastic/myeloproliferative (MDS/MPN) with ring sideroblasts and thrombocytopenia (RS-T), HIV-negative patient treated with the combination of CHOP and bortezomib. Read More

View Article
November 2018

AIDS-Associated Malignancies.

Cancer Treat Res 2019 ;177:1-21

Department of Dermatology, University of Texas Health Sciences Center at Houston, Houston, TX, 77030, USA.

Malignancies were one of the earliest recognized manifestations that led to the description of the acquired immune deficiency syndrome (AIDS). The majority of cancers in AIDS patients are associated with coinfection with oncogenic viruses, such as Epstein-Barr virus, human herpesvirus 8, and human papillomavirus, with resulting malignancies occurring secondary to diminished immune surveillance against viruses and virus-infected tumor cells. Over 50% of AIDS lymphomas are associated with Epstein-Barr virus (EBV) and/or HHV8 infection. Read More

View Article
January 2019

[Recent advances in pediatric non-Hodgkin lymphoma. Report on a retrospective single-center cohort and review of the literature].

Magy Onkol 2018 Dec 15;62(4):204-213. Epub 2018 Oct 15.

Gyermekgyógyászati Intézet, Gyermekhematológiai-onkológiai nem önálló Tanszék, Debreceni Egyetem, Általános Orvostudományi Kar, Debrecen, Hungary.

Classification, staging and treatment response criteria of pediatric NHL have been revised. Long-term survival reaches ~90% at the expense of severe acute toxicities. The outcome of refractory and relapsed cases is poor. Read More

View Article
December 2018
1 Read

Siblings' Experiences of Everyday Life in a Family Where One Child Is Diagnosed With Blood Cancer: A Qualitative Study.

J Pediatr Oncol Nurs 2018 Dec 12:1043454218818067. Epub 2018 Dec 12.

3 University Hospital Ghent, Ghent, Belgium.

Background: Childhood cancer not only presents challenges to the life of the child with cancer but also to the siblings' daily family life. The aim of the current study was to gain a better understanding of siblings' experiences of living in a family where one child has been diagnosed with blood cancer.

Method: Ten siblings of children with leukemia or non-Hodgkin lymphoma completed a semistructured interview about their everyday family life experiences postdiagnosis. Read More

View Article
December 2018

Alteration of gene expression profile in CD3 T-cells after downregulating MALT1.

Immunotargets Ther 2018 20;7:77-81. Epub 2018 Nov 20.

Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, 510632, People's Republic of China,

Background: T cell immunodeficiency is a common feature in patients with different kinds of hematological disease such as T cell non-Hodgkin lymphoma (T-NHL), B cells NHL (B-NHL), NK/T cell NHL (NK/T-CL) and acute myeloid leukemia (AML). In our recent research, we found that significantly lower expression levels in MALT1 and NF-κB were related to suppression of T cell activation. Therefore, this study was conducted to further investigate the role of downregulating MALT1 in the development of immunodeficiency in T cells. Read More

View Article
November 2018
1 Read

Effect of inotuzumab ozogamicin on the QT interval in patients with hematologic malignancies using QTc-Concentration Modelling.

Br J Clin Pharmacol 2018 Dec 8. Epub 2018 Dec 8.

Pfizer Oncology, Collegeville, PA, USA.

Aim: To characterize the effect of inotuzumab ozogamicin on QT interval in patients with B-cell malignancies.

Methods: Data were pooled from three clinical studies including 250 patients (N=2743) who received inotuzumab ozogamicin monotherapy. Patients with relapsed/refractory acute lymphoblastic leukaemia (NCT01564784 and NCT01363297) received 1. Read More

View Article
December 2018

CANCER INCIDENCE IN NORTHERN UGANDA (2013- 2016).

Int J Cancer 2018 Dec 10. Epub 2018 Dec 10.

African Cancer Registry Network, Oxford, United Kingdom.

Gulu Cancer Registry was established in 2014 to assess the incidence and survival of cancer in 4 districts of the Acholi Sub-region of northern Uganda. Here we report the results of the first 4 years of registration (2013-2016) in this largely rural population of 771,514. In total there were 1,627 cases of cancers registered; 644 among men (corresponding to an ASR of 106. Read More

View Article
December 2018

Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies.

Int J Hematol 2018 Dec 8. Epub 2018 Dec 8.

Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan.

We evaluated clinical outcomes of disseminated intravascular coagulation (DIC) in patients with hematological malignancies treated with synthetic protease inhibitors (SPIs) and compared the effects of gabexate mesilate (FOY) and nafamostat mesilate (FUT). We retrospectively examined 127 patients [acute myeloid leukemia (n = 48), acute lymphoblastic leukemia (n = 25), and non-Hodgkin lymphoma (n = 54)] with DIC, who were diagnosed according to Japanese Ministry of Health, Labour and Welfare criteria and treated with SPIs [FOY (n = 55) and FUT (n = 72)] at our hospital from 2006 to 2015. The DIC resolution rates on days 7 and 14 were 42. Read More

View Article
December 2018
1 Read

Mortality and Cancer Incidence in Carriers of Balanced Robertsonian Translocations: a National Cohort Study.

Am J Epidemiol 2018 Dec 7. Epub 2018 Dec 7.

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.

A balanced Robertsonian translocation results from fusion of two acrocentric chromosomes. Carriers are phenotypically normal, and are often diagnosed because of recurrent miscarriages, infertility or aneuploid offspring. Mortality and site-specific cancer risks in carriers have not been prospectively investigated. Read More

View Article
December 2018

Malignancies in adults living with HIV in Asia.

J Acquir Immune Defic Syndr 2018 Nov 29. Epub 2018 Nov 29.

Taipei Veterans General Hospital, Taipei, Taiwan.

BackgroundHaematological malignancies have continued to be highly prevalent among people living with HIV (PLHIV). This study assessed the occurrence, risk factors for, and outcomes of haematological and non-haematological malignancies in PLHIV in Asia.MethodsIncidence of malignancy after cohort enrolment was evaluated. Read More

View Article
November 2018

Serological Assessment of 18 Pathogens and Risk for AIDS-associated Non-Hodgkin Lymphoma.

J Acquir Immune Defic Syndr 2018 Nov 20. Epub 2018 Nov 20.

Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, California, USA.

Background: HIV infection is associated with increased susceptibility to common pathogens which may trigger chronic antigenic stimulation and hyperactivation of B-cells, events known to precede the development of AIDS-associated non-Hodgkin lymphoma (AIDS-NHL).

Methods: To explore whether cumulative exposure to infectious agents contributes to AIDS-NHL risk, we tested sera from 199 AIDS-NHL patients (pre-NHL, average lead-time 3.9 years) and 199 matched HIV-infected controls from the Multicenter AIDS Cohort Study (MACS), for anti-IgG responses to 18 pathogens using multiplex serology. Read More

View Article
November 2018

Risk of malignant lymphoma in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs and methotrexate
.

Int J Clin Pharmacol Ther 2018 Dec 11. Epub 2018 Dec 11.

Objective: This study investigated whether using biological disease-modifying antirheumatic drugs (bDMARDs) further increases the risk of malignant lymphoma in patients with rheumatoid arthritis undergoing methotrexate therapy using spontaneous adverse reaction databases in different countries.

Materials And Methods: Patient data were acquired from the US Food and Drug Administration's Adverse Event Reporting System (FAERS), the Japanese Adverse Drug Event Report (JADER), and the Canada Vigilance Adverse Reaction Online Database (CVARD) from the first quarter of 2004 to the end of 2015. Data subset analysis was performed to investigate whether the use of bDMARDs further increased the risk of malignant lymphoma in patients receiving methotrexate therapy. Read More

View Article
December 2018
2 Reads

Pemphigus and hematologic malignancies: A population-based study of 11,859 patients.

Authors:
Eden Lake

J Am Acad Dermatol 2018 Dec 3. Epub 2018 Dec 3.

Loyola University Medical Center Dermatology, 321 N La Grange Rd, La Grange Park, IL. Electronic address:

•Hematologic malignancies have been reported sporadically in patients with pemphigus.•In the current study, significant associations were observed between pemphigus and chronic leukemia, multiple myeloma, and non-Hodgkin lymphoma.•Further research is needed to confirm these findings in other cohorts. Read More

View Article
December 2018
7 Reads

Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma.

Br J Haematol 2018 Dec 5. Epub 2018 Dec 5.

Division of Oncology & Hematology, University of Nebraska Medical Center, Omaha, NE, USA.

Relapsed or refractory non-Hodgkin lymphomas (NHLs) often carry poor prognosis and pose management challenges. We evaluated the safety and efficacy of dasatinib, a broad-spectrum multi-kinase inhibitor in relapsed/refractory NHL with correlative genomic analysis in a Phase I/II trial. The study included 33 patients with various sub-types of NHL who had received at least one prior therapy. Read More

View Article
December 2018
6 Reads

Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome.

Cell Death Dis 2018 Dec 5;9(12):1178. Epub 2018 Dec 5.

Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy.

Cutaneous T-cell lymphoma is a group of incurable extranodal non-Hodgkin lymphomas that develop from the skin-homing CD4 T cell. Mycosis fungoides and Sézary syndrome are the most common histological subtypes. Although next-generation sequencing data provided significant advances in the comprehension of the genetic basis of this lymphoma, there is not uniform consensus on the identity and prevalence of putative driver genes for this heterogeneous group of tumors. Read More

View Article
December 2018
1 Read

Primary Non-Hodgkin Lymphoma of the Parotid Gland Masquerading Chronic Sialadenitis.

J Craniofac Surg 2018 Nov 30. Epub 2018 Nov 30.

Oral and Maxillofacial Surgery, 8AFDC, Kanpur, India.

View Article
November 2018
1 Read

Novel therapies for relapsed/refractory aggressive lymphomas.

Authors:
Jonathon B Cohen

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):75-82

Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.

Most patients with aggressive non-Hodgkin lymphoma will be cured with initial chemoimmunotherapy; however, most patients with relapsed disease will not be cured and will die as a result of their disease. In these cases, continued treatment with conventional chemotherapy is typically not of benefit and can contribute to significant toxicities and decreased quality of life for patients. Fortunately, a number of therapies are currently available or under investigation for this group of patients, ranging from oral tyrosine kinase inhibitors targeting multiple pathways within the malignant cells to adoptive cellular therapies that harness the patient's immune system to fight disease. Read More

View Article
November 2018
5 Reads

Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intent.

Leuk Lymphoma 2018 Dec 5:1-9. Epub 2018 Dec 5.

a Department of Medicine , University of Toronto , Toronto , Canada.

The association between obesity and survival in non-Hodgkin lymphoma is unclear. Using the Ontario Cancer Registry we conducted a retrospective analysis of incident cases of aggressive-histology B-cell lymphoma treated with a rituximab-containing regimen with curative intent between 2008-2016. 6246 patients were included. Read More

View Article
December 2018
3 Reads

Effect of PET/CT on the Management and Outcomes of Participants with Hodgkin and Aggressive Non-Hodgkin Lymphoma: A Multicenter Registry.

Radiology 2018 Dec 4:181519. Epub 2018 Dec 4.

From the Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital & Women's College Hospital, University of Toronto, 610 University Ave, Suite 3-960, Toronto, ON M5G 2M9, Canada (U.M., N.T.); Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada (A.P.); Department of Radiation Oncology, University of Toronto, and Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON, Canada (D.C.H.); Cancer Analytics, Analytics & Informatics (M.M., M.E., V.M.), Quality Measurement and Evaluation, Clinical Programs and Quality Initiatives (B.G.), Cancer Imaging, Clinical Programs and Quality Initiatives (P.M.), and Research Office, Analytics & Informatics (N.M., D.L.L.), Cancer Care Ontario, Toronto, ON, Canada; Department of Nuclear Medicine and Molecular Imaging, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada (A.S.); and Department of Oncology, Cancer Centre of Southeastern Ontario, Queen's University, Kingston, ON, Canada (J.D.).

Purpose To determine the relationship of PET/CT staging to the management and outcomes of participants with apparent limited-stage (LS) Hodgkin lymphoma (HL) or aggressive non-HL (ANHL) treated with curative intent. Materials and Methods This prospective multicenter registry included 850 participants (467 men and 383 women; median age, 54.1 years) from nine centers who had LS HL or ANHL on the basis of clinical data and CT, or with equivocal CT for advanced stage, who were considered for curative-intent first-line therapy. Read More

View Article
December 2018
2 Reads

An autopsy case of progressive multifocal leukoencephalopathy after rituximab therapy for malignant lymphoma.

Neuropathology 2018 Dec 3. Epub 2018 Dec 3.

Department of Pathology, Kurume University School of Medicine, Kurume, Japan.

Progressive multifocal leukoencephalopathy (PML) is a rare fatal demyelinating disease of the central nervous system caused by reactivation of the JC virus (JCV), which is named after the initials of the patient from whom the virus was first isolated. JCV is highly prevalent worldwide, infects humans in early childhood, and the infection persists throughout the course of life in latent form. The present paper deals with the second autopsy case report of rituximab-associated PML in Japan. Read More

View Article
December 2018
4 Reads

High-grade Burkitt Lymphoma Presenting as a Buttock Mass and Foot Drop.

Cureus 2018 Sep 26;10(9):e3368. Epub 2018 Sep 26.

Internal Medicine, St. Mary Mercy Hospital, Livonia, USA.

Burkitt lymphoma (BL), a highly aggressive B-cell non-Hodgkin lymphoma (NHL), usually presents in children and young adults with large extranodal masses involving jaw bones, gastrointestinal tract, and central nervous system. The three main subtypes of BL are endemic, sporadic, and immunodeficiency variant. Extranodal involvement is common in each variant of BL, although muscle tissue involvement is distinctly rare. Read More

View Article
September 2018
3 Reads

Hepatosplenic T-Cell Lymphoma in an Immunocompetent Male with Central Nervous System Invasion: A Rare Clinical Entity.

Cytometry B Clin Cytom 2018 Nov 30. Epub 2018 Nov 30.

Department of Hematology, Hamatological Research Center, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, China.

Hepatosplenic T-cell lymphoma (HSTCL) is a very rare non-Hodgkin lymphoma with an aggressive clinical course and poor prognosis. Patients of this disease usually presented with hepatosplenomegaly, which can be misdiagnosed or delayed. Bone marrow (BM) and peripheral blood (PB) are frequently involved, however, central nervous system (CNS) involvement is less common. Read More

View Article
November 2018
2 Reads

Cutaneous B-Cell Lymphoma.

Hematol Oncol Clin North Am 2019 Feb;33(1):149-161

Section of Dermatology, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA. Electronic address:

Primary cutaneous B-cell lymphomas are non-Hodgkin lymphomas that present in the skin without evidence of extracutaneous involvement at diagnosis. There are 3 types of primary cutaneous B-cell lymphomas: primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma, and primary cutaneous diffuse large B-cell lymphoma, leg-type. Because it is most frequently diagnosed on skin biopsy, intravascular large B-cell lymphoma is commonly included with pcBCL. Read More

View Article
February 2019
1 Read

Mycosis Fungoides and Sézary Syndrome: An Update.

Hematol Oncol Clin North Am 2019 Feb;33(1):103-120

Department of Dermatology, Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA.

Cutaneous T-cell lymphomas are a heterogeneous collection of non-Hodgkin lymphomas that arise from skin-tropic memory T lymphocytes. Among them, mycosis fungoides (MF) and Sézary syndrome (SS) are the most common malignancies. Diagnosis requires the combination of clinical, pathologic, and molecular features. Read More

View Article
February 2019
2 Reads

Trichodysplasia spinulosa in the setting of colon cancer.

Cutis 2018 Oct;102(4):262-264

Silver Falls Dermatology, Salem, Oregon; Department of Dermatopathology, Western University of Health Sciences, Lebanon, Oregon, USA.

Trichodysplasia spinulosa (TS) is a rare skin condition seen in immunosuppressed patients that is characterized by folliculocentric papules with central spiny spicules mainly on the face. We report the case of an 82-year-old woman with a history of treated non-Hodgkin lymphoma and a recent diagnosis of stage IV colon cancer. She presented with clinical and histopathologic findings consistent with TS occurring prior to starting immunosuppressive therapy for colon cancer. Read More

View Article
October 2018
1 Read

Role of consolidative radiation therapy for patients with mediastinal diffuse large B-cell lymphoma in the rituximab era.

J Cancer Res Ther 2018 Oct-Dec;14(6):1397-1402

Department of Radiation Oncology, Ege University Medical Faculty, Izmir, Turkey.

Background: The most common subtype of aggressive non-Hodgkin Lymphomas is diffuse large B-cell lymphoma (DLBCL). Mediastinal DLBCL is a distinct entity with unique clinical, pathologic, and genetic features and accepted as a subtype of DLBCL. The aim of this study is to evaluate the patients treated with consolidative radiotherapy (RT) after rituximab-containing chemotherapy for mediastinal DLBCL regarding treatment outcomes and relapse patterns. Read More

View Article
November 2018
2 Reads

Pregnancy-related factors and risk of B-cell non-Hodgkin lymphoma among women in Los Angeles.

Br J Haematol 2018 Nov 29. Epub 2018 Nov 29.

Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA.

View Article
November 2018
3 Reads

Primary Non-Hodgkin Lymphoma of Sphenoid Sinus Involving Cavernus Sinus and Clivus with Isolated 3rd Nerve Palsy.

Mymensingh Med J 2018 Oct;27(4):888-893

Dr Dhiman Chowdhury, Associate Professor, Department of Neurosurgery, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh; E-mail: dhiman_ns@ yahoo.com.

Lymphomas are group of malignant neoplasm having origins from lymphoreticular cells. B cell Non Hodgkin Lymphoma (BNHL) of sphenoid sinus as primary site for lymphomas are very rare and whenever involves comes usually with ocular manifestations. The proximity of the lesion to optic nerve and cavernous sinus present a high risk of developing unilateral ophthalmoplegia or even blindness. Read More

View Article
October 2018
7 Reads

Serum markers in the differential diagnosis of Waldenstrom macroglobulinemia and other IgM monoclonal gammopathies.

J Clin Lab Anal 2018 Nov 28:e22827. Epub 2018 Nov 28.

The Central Laboratory, Fujian Medical University Union Hospital, Fuzhou, China.

Background: IgM monoclonal gammopathy can be present in a broad spectrum of diseases. We evaluated the value of serum markers in the differential diagnosis of Waldenstrom macroglobulinemia (WM) and other types of IgM monoclonal gammopathies.

Methods: We included patients who were first admitted to hospital and identified as having IgM monoclonal gammopathy by serum immunofixation electrophoresis (sIFE). Read More

View Article
November 2018
2 Reads

Promising clinical outcomes of sequential and "Sandwich" chemotherapy and extended involved-field intensity-modulated radiotherapy in patients with stage I /II extranodal natural killer/T-cell lymphoma.

Cancer Med 2018 Nov 28. Epub 2018 Nov 28.

Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.

Background: The optimal treatment for the rare subtype of non-Hodgkin lymphoma, extranodal natural killer/T-cell lymphoma (ENKTL), nasal-type, has not been clearly defined. The purpose of the study was to investigate the efficacy of sequential and "Sandwich" chemotherapy and extended involved-field intensity-modulated radiotherapy (IMRT) in patients with stage I /II extranodal ENKTL, nasal-type.

Methods: One hundred and fifty-five patients with stage I /II nasal-type ENKTL were enrolled in the study, including 99 patients treated with sequential chemotherapy and extended involved-field IMRT (SCRT) and 56 patients with "Sandwich" chemotherapy and extended involved-field IMRT and chemotherapy (SCRCT). Read More

View Article
November 2018
4 Reads

A 4 or 5 Deauville score assessed by (18)F-FDG-PET CT early post-allotransplant is highly predictive of relapse in lymphoma patients.

Biol Blood Marrow Transplant 2018 Nov 24. Epub 2018 Nov 24.

Hematology Department, CHU, Nantes, France; Nantes-Angers Cancer Research Center (CRCINA), University of Nantes, Inserm UMR1232, 8 quai Moncousu, 44007 Nantes, France. Electronic address:

The impact of early Fluorine-18 Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET-CT) status on survival after allogeneic transplantation for lymphoma is poorly reported.This retrospective study included all adult Hodgkin (HL) or non-Hodgkin (NHL) lymphoma patients (>18 years old) who benefited from FDG PET-CT before (within 1 month) and/or early (+3 months and within +6-9 months) after Allo-SCT in our institution between 2005 and 2015 and who were still without documented progression nor relapse at the time of the FDG PET-CT. All FDG PET-CT were reviewed by a nuclear medicine expert in hematology and restaged according to the Deauville Scale. Read More

View Article
November 2018
1 Read

Reproductive factors, exogenous hormone use and risk of B-cell non-Hodgkin lymphoma in a cohort of women from the European Prospective Investigation into Cancer and Nutrition.

Am J Epidemiol 2018 Nov 27. Epub 2018 Nov 27.

Unit of Molecular Epidemiology and Genetics in Infections and Cancer. Cancer Epidemiology Research Programme. Bellvitge Biomedical Research Institute (IDIBELL). Catalan Institute of Oncology.

The role of hormonal factors in lymphoid neoplasms etiology remains unclear. Previous studies have yielded conflicting results, been underpowered to assess many lymphoma subtypes, or lacked detailed information on relevant exposures. Within the European Prospective Investigation into Cancer and Nutrition cohort, we analyzed comprehensive data collected at baseline (1992-2000) on reproductive factors and exogenous hormone use among 343,458 women, including 1,427 incident B-cell non-Hodgkin lymphomas (NHL) and its major subtypes identified after a mean follow-up of 14 years (through 2015). Read More

View Article
November 2018
5 Reads

Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis.

Hematology 2019 Dec;24(1):199-207

a Bone Marrow Transplantation Center , the First Affiliated Hospital, School of Medicine, Zhejiang University , Hangzhou , China.

Objectives: Multiple clinical trials have been conducted to investigate the therapeutic effects of blinatumomab on acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL). We did a meta-analysis including 8 clinical trials to verify the efficacy and safety of blinatumomab in patients with relapsed/refractory ALL and NHL.

Methods: We searched and investigated all relevant publications from PubMed, Web of Science, Embase, and ClinicalTrials. Read More

View Article
December 2019
11 Reads
1.189 Impact Factor

Primary lymphoma of the skull base in Chinese: clinical, radiological, pathological and therapeutic experience in a series of 8 cases.

World Neurosurg 2018 Nov 23. Epub 2018 Nov 23.

Department of Neurosurgery. Electronic address:

Background: Primary lymphoma of the skull base (PLSB) is an extremely rare neoplasm, and not much is known about the clinical features, treatment strategies and prognoses of these lesions. The aim of this study was to investigate the manifestations and clinical outcomes of patients with PLSB in Chinese.

Methods: We retrospectively reviewed 8 consecutive patients with PLSB treated in our center between October 2008 and December 2016 and analyzed their clinical features, treatment strategies and prognoses. Read More

View Article
November 2018
4 Reads

Unusual behavior of diffuse large B-cell lymphoma as cardiac invasion with rapid spontaneous regression after fine needle aspiration cytology.

J Exp Ther Oncol 2018 Nov;12(4):287-290

Cardiology Department, Mansoura Faculty of Medicine, Mansoura University, Egypt.

Objective: Spontaneous regression (SR) of lymphoma is a rare phenomenon. While the precise mechanism of SR remains unknown, apoptosis may be associated with its process. Here, we present a case of a 52-year-old woman was admitted to our hospital with cough and orthopnea for 2 weeks. Read More

View Article
November 2018
5 Reads

Identification of LEM-14 inhibitor of the oncoprotein NSD2.

Biochem Biophys Res Commun 2018 Nov 21. Epub 2018 Nov 21.

Department of Genetic Engineering, School of Life Sciences, College of Natural Sciences, Kyungpook National University, Daegu, 41566, Republic of Korea. Electronic address:

The NSD family (NSD1, NSD2/MMSET/WHSC1, and NSD3/WHSC1L1) are histone lysine methyltransferases (HMTases) essential for chromatin regulation. The NSDs are oncoproteins, drivers of a number of tumors and are considered important drug-targets but the lack of potent and selective inhibitors hampers further therapeutic development and limits exploration of their biology. In particular, MMSET/NSD2 selective inhibition is being pursued for therapeutic interventions against multiple myeloma (MM) cases, especially in multiple myeloma t(4;14)(p16. Read More

View Article
November 2018
2 Reads